194 related articles for article (PubMed ID: 23734036)
1. Risk of acute kidney injury associated with the use of fluoroquinolones.
Bird ST; Etminan M; Brophy JM; Hartzema AG; Delaney JA
CMAJ; 2013 Jul; 185(10):E475-82. PubMed ID: 23734036
[TBL] [Abstract][Full Text] [Related]
2. Oral fluoroquinolones and risk of fibromyalgia.
Ganjizadeh-Zavareh S; Sodhi M; Spangehl T; Carleton B; Etminan M
Br J Clin Pharmacol; 2019 Jan; 85(1):236-239. PubMed ID: 30216492
[TBL] [Abstract][Full Text] [Related]
3. Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort.
Hsu SC; Chang SS; Lee MG; Lee SH; Tsai YW; Lin SC; Chen ST; Weng YC; Porta L; Wu JY; Lee CC
PLoS One; 2017; 12(9):e0183813. PubMed ID: 28873440
[TBL] [Abstract][Full Text] [Related]
4. Oral fluoroquinolones and risk of glaucoma.
Yang L; Etminan M; Mikelberg FS
J Glaucoma; 2014 Sep; 23(7):464-6. PubMed ID: 23632400
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolones and the risk of serious arrhythmia: a population-based study.
Lapi F; Wilchesky M; Kezouh A; Benisty JI; Ernst P; Suissa S
Clin Infect Dis; 2012 Dec; 55(11):1457-65. PubMed ID: 22865870
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.
Kaye JA; Castellsague J; Bui CL; Calingaert B; McQuay LJ; Riera-Guardia N; Saltus CW; Quinlan S; Holick CN; Wahl PM; Suzart K; Rothman KJ; Wallander MA; Perez-Gutthann S
Pharmacotherapy; 2014; 34(4):336-49. PubMed ID: 24865821
[TBL] [Abstract][Full Text] [Related]
7. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
Etminan M; Brophy JM; Samii A
Neurology; 2014 Sep; 83(14):1261-3. PubMed ID: 25150290
[TBL] [Abstract][Full Text] [Related]
8. Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Morales D; Pacurariu A; Slattery J; Pinheiro L; McGettigan P; Kurz X
JAMA Neurol; 2019 Jul; 76(7):827-833. PubMed ID: 31034074
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
Sodhi M; Sheldon CA; Carleton B; Etminan M
Neurology; 2017 Aug; 89(8):792-795. PubMed ID: 28754842
[TBL] [Abstract][Full Text] [Related]
10. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone.
Lee CC; Lee MT; Chen YS; Lee SH; Chen YS; Chen SC; Chang SC
JAMA Intern Med; 2015 Nov; 175(11):1839-47. PubMed ID: 26436523
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of the association between fluoroquinolones and tendon rupture: The magnitude of the effect with and without corticosteroids.
Persson R; Jick S
Br J Clin Pharmacol; 2019 May; 85(5):949-959. PubMed ID: 30682225
[TBL] [Abstract][Full Text] [Related]
12. Association Between Oral Fluoroquinolone Use and Retinal Detachment.
Raguideau F; Lemaitre M; Dray-Spira R; Zureik M
JAMA Ophthalmol; 2016 Apr; 134(4):415-21. PubMed ID: 26967005
[TBL] [Abstract][Full Text] [Related]
13. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study.
Paterson JM; Mamdani MM; Manno M; Juurlink DN;
CMAJ; 2012 Oct; 184(14):1565-70. PubMed ID: 22891208
[TBL] [Abstract][Full Text] [Related]
15. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.
Seeger JD; West WA; Fife D; Noel GJ; Johnson LN; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):784-92. PubMed ID: 16456878
[TBL] [Abstract][Full Text] [Related]
16. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Alshammari TM; Larrat EP; Morrill HJ; Caffrey AR; Quilliam BJ; LaPlante KL
Am J Health Syst Pharm; 2014 Jan; 71(1):37-43. PubMed ID: 24352180
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.
Assimon MM; Pun PH; Wang LC; Al-Khatib SM; Brookhart MA; Weber DJ; Winkelmayer WC; Flythe JE
JAMA Cardiol; 2022 Jan; 7(1):75-83. PubMed ID: 34668928
[TBL] [Abstract][Full Text] [Related]
18. Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.
Morales DR; Slattery J; Pacurariu A; Pinheiro L; McGettigan P; Kurz X
Clin Drug Investig; 2019 Feb; 39(2):205-213. PubMed ID: 30465300
[TBL] [Abstract][Full Text] [Related]
19. Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study.
Son N; Choi E; Chung SY; Han SY; Kim B
BMC Cardiovasc Disord; 2022 Feb; 22(1):44. PubMed ID: 35152888
[TBL] [Abstract][Full Text] [Related]
20. Oral Fluoroquinolones and the Risk of Uveitis.
Sandhu HS; Brucker AJ; Ma L; VanderBeek BL
JAMA Ophthalmol; 2016 Jan; 134(1):38-43. PubMed ID: 26512796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
